Analyst consensus rating
Oruka Therapeutics Analyst Rating: Strong Buy
ORKA is rated Strong Buy by 12 analysts with a $153.75 target. As of 2026-09-02.
Direct answer
Oruka Therapeutics's consensus rating is Strong Buy.
12 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $153.75.
Forecast evidence checked September 2, 2026.
Get free Oruka Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $91.27
- Average price target
- $153.75
- High price target
- $200.00
- Low price target
- $102.00
- Low target gap
- +11.8%
- Target upside
- +68.5%
- High target gap
- +119.1%
- Target range width
- 107.4%
- Consensus rating
- Strong Buy
- Analysts
- 12
- Evidence date
- September 2, 2026
- Valid through
- September 9, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Oruka Therapeutics?
Oruka Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $153.75.
How far are Oruka Therapeutics's low and high targets from the recorded price?
The low target implies +11.8%, while the high target implies +119.1%.
How many analysts are included in Oruka Therapeutics's consensus?
The verified consensus includes 12 analysts.
How is Oruka Therapeutics's target upside or downside calculated?
The average target of $153.75 is divided by the recorded price of $91.27, then one is subtracted to produce +68.5%. This does not guarantee a future return.
When was Oruka Therapeutics's analyst forecast verified?
The data was verified on 2026-09-02. The dataset is valid through 2026-09-09.